Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints.
作者信息
Passaro Antonio, de Marinis Filippo
机构信息
Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
出版信息
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S334-S338. doi: 10.21037/tlcr.2019.06.04.
Abstract
摘要
相似文献
1
Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints.通过评估生存终点寻找表皮生长因子受体（EGFR）阳性非小细胞肺癌的治疗新途径
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S334-S338. doi: 10.21037/tlcr.2019.06.04.
2
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.JO22903研究的最终总生存期，这是一项针对日本EGFR突变阳性非小细胞肺癌患者的一线厄洛替尼的II期开放标签研究。
Int J Clin Oncol. 2017 Feb;22(1):70-78. doi: 10.1007/s10147-016-1039-0. Epub 2016 Sep 22.
3
Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.阿法替尼用于表皮生长因子受体突变阳性非小细胞肺癌的一线治疗：临床证据综述
Ther Adv Respir Dis. 2016 Jun;10(3):256-64. doi: 10.1177/1753465816634545. Epub 2016 Feb 28.
4
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.阿法替尼治疗 EGFR FISH 阳性非小细胞肺癌的 II 期研究。阿法替尼，一种不可逆的 ErbB 家族阻滞剂。
J Thorac Oncol. 2015 Apr;10(4):665-72. doi: 10.1097/JTO.0000000000000442.
5
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.肺癌的新辅助和辅助表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗。
Transl Lung Cancer Res. 2015 Feb;4(1):82-93. doi: 10.3978/j.issn.2218-6751.2014.11.08.
6
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.厄洛替尼和吉非替尼用于治疗先前化疗后进展的非小细胞肺癌（英国国家卫生与临床优化研究所技术评估162和175回顾）：一项系统评价与经济学评估
Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470.
7
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).一项评估一线厄洛替尼用于表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌（NSCLC）日本患者的前瞻性、II 期、开放标签研究（JO22903）。
Lung Cancer. 2013 Oct;82(1):109-14. doi: 10.1016/j.lungcan.2013.07.003. Epub 2013 Jul 31.
8
Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.FLEX 研究中晚期非小细胞肺癌患者中 EGFR 表达、EGFR 突变状态与化疗联合西妥昔单抗疗效的关系。
J Thorac Oncol. 2014 May;9(5):717-24. doi: 10.1097/JTO.0000000000000141.
9
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.在 EGFR 突变阳性的晚期非小细胞肺癌患者中使用 lazertinib：一项首次人体、开放标签、多中心、1-2 期剂量递增和剂量扩展部分的研究结果。
Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3.
10
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).在法国前瞻性队列研究（ERMETIC 项目-第 2 部分）中，对接受厄洛替尼治疗的晚期非小细胞肺癌患者进行系统 EGFR 和 KRAS 突变评估对无进展生存期和总生存期的影响。
J Thorac Oncol. 2012 Oct;7(10):1490-502. doi: 10.1097/JTO.0b013e318265b2b5.
引用本文的文献
1
Establishment of multiplex allele-specific blocker PCR for enrichment and detection of 4 common mutations in non-small cell lung cancer.建立多重等位基因特异性阻断PCR法用于富集和检测非小细胞肺癌中的4种常见突变。
Ann Transl Med. 2020 Nov;8(22):1509. doi: 10.21037/atm-20-6754.
本文引用的文献
1
Brain metastases in EGFR-positive non-small cell lung cancer: the way to the becomes less winding.表皮生长因子受体（EGFR）阳性非小细胞肺癌中的脑转移：通往（此处原文不完整）的道路不再那么曲折。
Ann Transl Med. 2019 Jul;7(Suppl 3):S80. doi: 10.21037/atm.2019.04.04.
2
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.未经治的表皮生长因子受体突变型晚期非小细胞肺癌患者奥希替尼对比标准治疗 EGFR-TKI 的治疗进展后结局。
Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.
3
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.布加替尼与克唑替尼用于治疗间变性淋巴瘤激酶阳性的非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.
4
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.未经治疗的表皮生长因子受体（EGFR）突变型晚期非小细胞肺癌患者中，中枢神经系统（CNS）对奥希替尼与标准表皮生长因子受体酪氨酸激酶抑制剂的反应。
J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118.
5
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.在一项比较达克替尼与吉非替尼用于治疗伴有表皮生长因子受体激活突变的晚期非小细胞肺癌患者的随机研究中，患者的总生存期得到改善。
J Clin Oncol. 2018 Aug 1;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994. Epub 2018 Jun 4.
6
EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.非小细胞肺癌中的表皮生长因子受体酪氨酸激酶抑制剂：聚焦临床药理学与耐药机制
Pharmacogenomics. 2018 Jun 1;19(8):727-740. doi: 10.2217/pgs-2018-0038. Epub 2018 May 22.
7
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.致癌基因成瘾的非小细胞肺癌患者的脑转移：发病率与治疗
Front Oncol. 2018 Apr 11;8:88. doi: 10.3389/fonc.2018.00088. eCollection 2018.
8
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?优化 EGFR 突变阳性 NSCLC 的治疗结局：应选择哪种酪氨酸激酶抑制剂及何时使用？
Future Oncol. 2018 May;14(11):1117-1132. doi: 10.2217/fon-2017-0636. Epub 2018 Jan 16.
9
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
10
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.达克替尼对比吉非替尼作为 EGFR 突变阳性非小细胞肺癌患者的一线治疗（ARCHER 1050）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.
Zotero 插件